Cordova-Delgado Miguel, Pinto Mauricio P, Regonesi Carlos, Cereceda Luis, Reyes José Miguel, Itriago Laura, Majlis Alejandro, Rodríguez Pablo, Fassler André, Mahave Mauricio, León María Elisa, Gallardo Jorge, Rodríguez Z María Paz, Berkovits Alejandro, Manque Patricio, Ríos Juvenal A, Garcia-Bloj Benjamín, Garrido Marcelo
Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330032, Chile.
Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago 8380494, Chile.
J Pers Med. 2022 Jan 31;12(2):195. doi: 10.3390/jpm12020195.
Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients ( = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.
测序技术和靶向治疗的重大进展加速了肿瘤学进入精准医学和“生物标志物驱动”治疗时代。然而，这种方法对日常临床的影响尚未确定。大多数精准肿瘤学报告基于发达国家，通常涉及转移性、难治性或无法治愈的癌症患者。此外，在许多情况下，这些研究中的种族和族裔情况通常未被报告，关于这一主题的真实世界证据也很匮乏。在此，我们报告了总共202例智利晚期难治性癌症患者的数据。我们回顾性地收集了来自NGS检测和免疫组化的患者数据，以确定将从靶向治疗中获益的患者比例。我们的队列中总共纳入了超过20种肿瘤类型，37%的患者（n = 74）显示出潜在可操作的改变，包括标签内、标签外和免疫检查点抑制剂推荐。我们的研究结果与之前的报告如癌症基因组图谱（TCGA）一致。据我们所知，这是拉丁美洲此类的第一份报告，提供了真实世界证据来估计可能从精准肿瘤学中获益的难治性肿瘤患者的百分比。尽管这种方法在智利仍处于起步阶段，但我们强烈鼓励在我国实施肿瘤突变讨论组，以便为晚期难治性患者提供更多治疗选择。
